Ares Financial Consulting, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Ares Financial Consulting, LLC
- $105 Billion
- Q4 2025
A detailed history of Ares Financial Consulting, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Ares Financial Consulting, LLC holds 12 shares of CRNX stock, worth $522. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12Holding current value
$522% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
247Shares Held
93MCall Options Held
1.02MPut Options Held
204K-
Vanguard Group Inc Valley Forge, PA9.14MShares$398 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.38MShares$365 Million0.06% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.48MShares$282 Million2.29% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$271 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA5.77MShares$251 Million1.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.34B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...